Product Code: 21EL-674-4035
Please note: This is a Single Viewer registration for one participant for the on-demand version of this program. Access instructions for the on-demand version of this program will be provided via email approximately 5-10 business days after the live program has occurred and the on-demand version is available. If registering after the on-demand version is available, immediate access is granted via the AABB Education Website at https://education.aabb.org.
If you registered for the live program you do not need to register for this on-demand eCast (access to the on-demand eCast was included with the live program registration).If you are interested in presenting this program to a group, please see the “eCast Registration Form– Group Viewing” form on the program page.
Program Description: Sickle cell disease is affected approximately 100,000 people in the United States. It is a major public health concern and the patients have a significant morbidity and mortality. At this time, transfusion of red blood cells (RBCs) is one of the main treatment strategies for this disease. However, transfusion is potentially associated with multiple complications, including transfusion-transmitted infections and alloimmunizations. Given that there are few quality studies investigated the effect of simple vs. exchange transfusion in patients with sickle cell disease, this program will summarize the current data and expert opinion on the use of each treatment modality. Key considerations that physicians should be aware of when choosing between treatment options as well as challenges in pediatric patients will also be addressed. Lastly, novel therapies in the treatment of sickle cell disease, including cellular therapies, will be discussed.
